Patent ID: 8163509

Claim:
A method of identifying a patient with cancer who is most likely to benefit from treatment with an IGF-1R kinase inhibitor, comprising: (1) obtaining a sample of the patient's tumor, (2) determining if tumor cells of the sample exhibit the following classifiers of tumor cells that are more likely to be sensitive to growth inhibition by an IGF-1R kinase inhibitor: (a) higher expression level of the PROM1 gene than the MT1E gene; (b) higher expression level of the LY75 gene than the OXCT1 gene; (c) higher expression level of the HSD17B2 gene than the CALD1 gene; (d) increased levels of IGF-1R gene copy number relative to ploidy; (e) the absence of a mutant K-RAS gene; and (3) identifying the patient as one most likely to benefit from treatment with an IGF-1R kinase inhibitor if at least four of the five assessed classifiers are present in the tumor cells.